In 2014, technetium-99m tilmanocept (TcTM) replaced technetium-99m sulfur colloid (TcSC) as the standard lymphoscintigraphy (LS) mapping agent in melanoma patients undergoing sentinel lymph node biopsy (SLNB). The aim of this study was to examine differences in mapping time, intra-operative identification of sentinel lymph node (SLN), and false negative rate (FNR) between patients who underwent SLNB with TcTM compared to TcSC.

Methods

Patients who underwent SLNB between 2010 and 2018 were retrospectively identified. Patient demographic, tumor, and imaging data was stratified by receipt of TcSC (n = 258) or TcTM (n = 133). Student's t test and χ² test were used to compare characteristics and outcomes.

Results

Both cohorts were similar in demographic, primary tumor characteristics, and total number of SLN identified (TcTM 3.56 vs. TcSC 3.28, p = 0.244). TcTM was associated with significantly shorter LS mapping times (51.8 vs. 195.1 min, p < 0.01). There was no significant difference in the number of patients with positive SLN (TcTM 11.3 vs. TcSC 17.4%, p = 0.109) and the FNR was similar between both groups (TcTM 25% vs. TcSC 22%).

Conclusion

TcTM was associated with significantly shorter LS mapping time while identifying similar numbers of SLN. Our results support further study to ensure similar FNR and oncologic outcomes between agents.

CONFLICT OF INTERESTS

Georgia M. Beasley: advisory board Regeneron (2020), Cardinal Health (2018). Berger-Advisory Board, Cardinal Health.

Open Research

DATA AVAILABILITY STATEMENT

Due to the nature of this study, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.

REFERENCES

1 National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer stat facts: melanoma of the skin. Accessed October 22, 2020. https://seer.cancer.gov/statfacts/html/melan.html
Google Scholar
2Quartuccio N, Siracusa M, Pappalardo M, Arnone A, Arnone G. Sentinel Node identification in melanoma: current clinical impact, new emerging SPECT radiotracers and technological advancements. an update of the last decade. Curr Radiopharm. 2020; 13(1): 32-41.
10.2174/1874471012666191015100837
CAS PubMed Web of Science® Google Scholar
3 National Comprehensive Cancer Network. Cutaneous melanoma (Version 4). October 22, 2020. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
Google Scholar
4Surasi DS, O'Malley J, Bhambhvani P. 99 mTc-tilmanocept: a novel molecular agent for lymphatic mapping and sentinel lymph node localization J Nucl Med Technol. 2015; 43(2): 87-91.
10.2967/jnmt.115.155960
PubMed Web of Science® Google Scholar
5Baker JL, Pu M, Tokin CA, et al. Comparison of [(99 m)Tc]tilmanocept and filtered [(99 m)Tc]sulfur colloid for identification of SLNs in breast cancer patients Ann Surg Oncol. 2015; 22(1): 40-45.
10.1245/s10434-014-3892-2
PubMed Web of Science® Google Scholar
6Unkart JT, Hosseini A, Wallace AM. Tc-99m tilmanocept versus Tc-99m sulfur colloid in breast cancer sentinel lymph node identification: results from a randomized, blinded clinical trial. J Surg Oncol. 2017; 116(7): 819-823.
10.1002/jso.24735
CAS PubMed Web of Science® Google Scholar
7Sondak VK, King DW, Zager JS, et al. Combined analysis of phase III trials evaluating [(9)(9)mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013; 20(2): 680-688.
10.1245/s10434-012-2612-z
PubMed Web of Science® Google Scholar
8Wallace AM, Hoh CK, Vera DR, Darrah DD, Schulteis G. Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003; 10(5): 531-538.
10.1245/ASO.2003.07.012
PubMed Web of Science® Google Scholar
9Silvestri C, Christopher A, Intenzo C, et al. Consecutive case series of melanoma sentinel node biopsy for lymphoseek compared to sulfur colloids. J Surg Res. 2019; 233: 149-153.
10.1016/j.jss.2018.07.042
PubMed Web of Science® Google Scholar
10Fincher TR, O'Brien JC, McCarty TM, et al. Patterns of drainage and recurrence following sentinel lymph node biopsy for cutaneous melanoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2004; 130(7): 844-848.
10.1001/archotol.130.7.844
PubMed Web of Science® Google Scholar
11Manca G, Rubello D, Romanini A, et al. Sentinel lymph node mapping in melanoma: the issue of false-negative findings. Clin Nucl Med. 2014; 39(7): e346-e354.
10.1097/RLU.0000000000000366
PubMed Web of Science® Google Scholar
12Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014; 370(7): 599-609.
10.1056/NEJMoa1310460
CAS PubMed Web of Science® Google Scholar
13Wallace AM, Hoh CK, Vera DR, Darrah DD, Schulteis G. Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003; 10(5): 531-538.
10.1245/ASO.2003.07.012
PubMed Web of Science® Google Scholar
14Wallace AM, Hoh CK, Ellner SJ, Darrah DD, Schulteis G, Vera DR. Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol. 2007; 14(2): 913-921.
10.1245/s10434-006-9099-4
PubMed Web of Science® Google Scholar
15Leong SP, Kim J, Ross M, et al. A phase 2 study of (99 m)Tc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer Ann Surg Oncol. 2011; 18(4): 961-969.
10.1245/s10434-010-1524-z
PubMed Web of Science® Google Scholar
16Unkart JT, Proudfoot J, Wallace AM. Outcomes of “one-day” vs “two-day” injection protocols using Tc-99m tilmanocept for sentinel lymph node biopsy in breast cancer. Breast J. 2018; 24(4): 526-530.
10.1111/tbj.13002
PubMed Web of Science® Google Scholar
17Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013; 310(14): 1455-1461.
10.1001/jama.2013.278932
CAS PubMed Web of Science® Google Scholar
18Murphy BL, Woodwick AR, Murphy KM, et al. 99 m)Tc-tilmanocept versus (99m)Tc-sulfur colloid in lymphoscintigraphy: sentinel lymph node identification and patient-reported pain. J Nucl Med Technol. 2019; 47(4): 300-304.
10.2967/jnmt.118.225342
PubMed Web of Science® Google Scholar
19Miller MW, Vetto JT, Monroe MM, Weerasinghe R, Andersen PE, Gross ND. False-negative sentinel lymph node biopsy in head and neck melanoma. Otolaryngol Head Neck Surg. 2011; 145(4): 606-611.
10.1177/0194599811411878
PubMed Web of Science® Google Scholar
20Sinnamon AJ, Neuwirth MG, Bartlett EK, et al. Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma. J Surg Oncol. 2017; 116(7): 848-855.
10.1002/jso.24743
PubMed Web of Science® Google Scholar
21Vermeeren L, Valdés Olmos RA, Klop WM, et al. SPECT/CT for sentinel lymph node mapping in head and neck melanoma. Head Neck. 2011; 33(1): 1-6.
10.1002/hed.21392
PubMed Web of Science® Google Scholar
22ACS Clinical Research Program, M. H. G. Katz. Operative standards for cancer surgery: Esophagus, melanoma, rectum, stomach, thyroid. Vol II. Lippincott Williams & Wilkins; 2018: 352.
Google Scholar
23McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000; 18(13): 2560-2566.
10.1200/JCO.2000.18.13.2560
CAS PubMed Web of Science® Google Scholar
24He PS, Li F, Li GH, Guo C, Chen TJ. The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review. BMC Cancer. 2016; 16: 107.
10.1186/s12885-016-2137-0
PubMed Web of Science® Google Scholar
25Cox CE, Dupont E, Whitehead GF, et al. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J. 2002; 8(2): 88-91.
10.1046/j.1524-4741.2002.08203.x
PubMed Google Scholar
26Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015; 261(3): 547-552.
10.1097/SLA.0000000000000551
PubMed Web of Science® Google Scholar
27Hutchinson JR, Chagpar AB, Scoggins CR, et al. Surgeon and community factors affecting breast cancer sentinel lymph node biopsy. Am J Surg. 2005; 190(6): 903-906.
10.1016/j.amjsurg.2005.08.018
PubMed Web of Science® Google Scholar

Citing Literature

Volume125, Issue4

March 15, 2022

Pages 712-718

How much time is enough? Sentinel lymph node mapping time depends on the radiotracer agent

Abstract

Background

Methods

Results

Conclusion

CONFLICT OF INTERESTS

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

How much time is enough? Sentinel lymph node mapping time depends on the radiotracer agent

Abstract

Background

Methods

Results

Conclusion

CONFLICT OF INTERESTS

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature

References

Related

Information